



## Clinical trial results:

### Effect of Patient Education on Treatment Adherence and Satisfaction among Acne Patients Receiving Once-Daily Epiduo™ Gel Treatment in Primary Care Clinics

#### Summary

|                          |                |
|--------------------------|----------------|
| EudraCT number           | 2014-002509-39 |
| Trial protocol           | GB             |
| Global end of trial date | 08 June 2015   |

#### Results information

|                                |                 |
|--------------------------------|-----------------|
| Result version number          | v1 (current)    |
| This version publication date  | 01 January 2017 |
| First version publication date | 01 January 2017 |

#### Trial information

##### Trial identification

|                       |                  |
|-----------------------|------------------|
| Sponsor protocol code | RD.03.SPR.102710 |
|-----------------------|------------------|

##### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT02307266 |
| WHO universal trial number (UTN)   | -           |

Notes:

#### Sponsors

|                              |  |
|------------------------------|--|
| Sponsor organisation name    | Galderma R&D   |
| Sponsor organisation address | 2400 route des colles, Biot, France, 06110                                       |
| Public contact               | Clinical Projet Manager, GALDERMA R&D, 33 493957068, gaelle.charier@galderma.com |
| Scientific contact           | Clinical Projet Manager, GALDERMA R&D, 33 493957068, gaelle.charier@galderma.com |

Notes:

#### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

---

**Results analysis stage**

---

|  |              |
|--|--------------|
| Analysis stage                                       | Final        |
| Date of interim/final analysis                       | 01 July 2016 |
| Is this the analysis of the primary completion data? | Yes          |
| Primary completion date                              | 08 June 2015 |
| Global end of trial reached?                         | Yes          |
| Global end of trial date                             | 08 June 2015 |
| Was the trial ended prematurely?                     | No           |

Notes:

---

**General information about the trial**

---

Main objective of the trial:

The main objective of the study is to evaluate the effect of a supplementary patient education intervention (in addition to the standard-of-care patient education) on treatment adherence and satisfaction among acne patients receiving once daily Epiduo Gel treatment in primary care clinics.

Protection of trial subjects:

All study participants were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

|   |                  |
|---|------------------|
| Actual start date of recruitment                          | 26 November 2014 |
| Long term follow-up planned                               | No               |
| Independent data monitoring committee (IDMC) involvement? | No               |

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

|                                      |                    |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | United Kingdom: 97 |
| Worldwide total number of subjects   | 97                 |
| EEA total number of subjects         | 97                 |

Notes:

---

**Subjects enrolled per age group**

|   |    |
|---|----|
| In utero                                  | 0  |
| Preterm newborn - gestational age < 37 wk | 0  |
| Newborns (0-27 days)                      | 0  |
| Infants and toddlers (28 days-23 months)  | 0  |
| Children (2-11 years)                     | 0  |
| Adolescents (12-17 years)                 | 39 |
| Adults (18-64 years)                      | 58 |
| From 65 to 84 years                       | 0  |
| 85 years and over                         | 0  |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

No screening

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall trial (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Randomised - controlled        |
| Blinding used                | Not blinded                    |

### Arms

|                              |     |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

|                  |  |
|------------------|--|
| <b>Arm title</b> | Standard of care + supplementary education |
|------------------|--|

Arm description: -

|  |  |
|--|--|
| Arm type                               | Experimental                           |
| Investigational medicinal product name | Adapalene 0.1% / Benzoyl peroxide 2.5% |
| Investigational medicinal product code |  |
| Other name                             | Epiduo                                 |
| Pharmaceutical forms                   | Gel                                    |
| Routes of administration               | Topical use                            |

Dosage and administration details:

application on the face, once daily

|                  |                  |
|------------------|------------------|
| <b>Arm title</b> | Standard of care |
|------------------|------------------|

Arm description: -

|  |  |
|--|--|
| Arm type                               | Experimental                           |
| Investigational medicinal product name | Adapalene 0.1% / Benzoyl peroxide 2.5% |
| Investigational medicinal product code |  |
| Other name                             | Epiduo                                 |
| Pharmaceutical forms                   | Gel                                    |
| Routes of administration               | Topical use                            |

Dosage and administration details:

application on the face, once daily

|                  |                                      |
|------------------|--------------------------------------|
| <b>Arm title</b> | Standard of care + additional visits |
|------------------|--------------------------------------|

Arm description: -

|  |  |
|--|--|
| Arm type                               | Experimental                           |
| Investigational medicinal product name | Adapalene 0.1% / Benzoyl peroxide 2.5% |
| Investigational medicinal product code |  |
| Other name                             | Epiduo                                 |
| Pharmaceutical forms                   | Gel                                    |
| Routes of administration               | Topical use                            |

Dosage and administration details:

application on the face, once daily

| Number of subjects in period 1 | Standard of care +<br>supplementary<br>education | Standard of care | Standard of care +<br>additional visits |
|--------------------------------|--|------------------|---|
|                                |  |                  |   |
| Started                        | 33   | 33               | 31                                      |
| Completed                      | 25   | 32               | 25                                      |
| Not completed                  | 8  | 1                | 6                                       |
| Consent withdrawn by subject   | 2  | -                | 1                                       |
| Adverse event, non-fatal       | 3  | 1                | 5                                       |
| Lost to follow-up              | 3  | -                | -                                       |

## Baseline characteristics

### Reporting groups

|                                |  |
|--------------------------------|--|
| Reporting group title          | Standard of care + supplementary education |
| Reporting group description: - |  |
| Reporting group title          | Standard of care                           |
| Reporting group description: - |  |
| Reporting group title          | Standard of care + additional visits       |
| Reporting group description: - |  |

| Reporting group values                             | Standard of care + supplementary education | Standard of care | Standard of care + additional visits |
|--|--|------------------|--------------------------------------|
| Number of subjects                                 | 33   | 33               | 31                                   |
| Age categorical                                    |  |                  |                                      |
| Units: Subjects                                    |  |                  |                                      |
| In utero   | 0  | 0                | 0                                    |
| Preterm newborn infants (gestational age < 37 wks) | 0  | 0                | 0                                    |
| Newborns (0-27 days)                               | 0  | 0                | 0                                    |
| Infants and toddlers (28 days-23 months)           | 0  | 0                | 0                                    |
| Children (2-11 years)                              | 0  | 0                | 0                                    |
| Adolescents (12-17 years)                          | 8  | 14               | 17                                   |
| Adults (18-64 years)                               | 25   | 19               | 14                                   |
| From 65-84 years                                   | 0  | 0                | 0                                    |
| 85 years and over                                  | 0  | 0                | 0                                    |
| Age continuous                                     |  |                  |                                      |
| Units: years                                       |  |                  |                                      |
| arithmetic mean                                    | 24.1                                       | 21               | 22.5                                 |
| standard deviation                                 | ± 9.6                                      | ± 7.9            | ± 11.1                               |
| Gender categorical                                 |  |                  |                                      |
| Units: Subjects                                    |  |                  |                                      |
| Female   | 22   | 26               | 19                                   |
| Male   | 11   | 7                | 12                                   |
| Race   |  |                  |                                      |
| Units: Subjects                                    |  |                  |                                      |
| White  | 29   | 26               | 27                                   |
| Asian  | 3  | 6                | 4                                    |
| Other  | 1  | 1                | 0                                    |
| Skin phototype                                     |  |                  |                                      |
| Units: Subjects                                    |  |                  |                                      |
| Phototype I  | 2  | 3                | 2                                    |
| Phototype II                                       | 11   | 9                | 11                                   |
| Phototype III                                      | 14   | 13               | 12                                   |
| Phototype IV                                       | 5  | 6                | 4                                    |
| Phototype V  | 1  | 2                | 2                                    |
| Investigator Global Assessment                     |  |                  |                                      |
| Investigator Global Assessment of acne             |  |                  |                                      |
| Units: Subjects                                    |  |                  |                                      |

|   |       |       |       |
|---|-------|-------|-------|
| 1: Almost clear                                       | 8     | 1     | 3     |
| 2: Mild   | 17    | 22    | 20    |
| 3: Moderate   | 8     | 10    | 8     |
| Acne history  |       |       |       |
| Units: years  |       |       |       |
| arithmetic mean                                       | 5.7   | 4.4   | 4.7   |
| standard deviation                                    | ± 9.3 | ± 4.6 | ± 5.6 |
| <b>Reporting group values</b>                         |       |       |       |
| Number of subjects                                    | 97    |       |       |
| Age categorical                                       |       |       |       |
| Units: Subjects                                       |       |       |       |
| In utero  | 0     |       |       |
| Preterm newborn infants<br>(gestational age < 37 wks) | 0     |       |       |
| Newborns (0-27 days)                                  | 0     |       |       |
| Infants and toddlers (28 days-23<br>months)           | 0     |       |       |
| Children (2-11 years)                                 | 0     |       |       |
| Adolescents (12-17 years)                             | 39    |       |       |
| Adults (18-64 years)                                  | 58    |       |       |
| From 65-84 years                                      | 0     |       |       |
| 85 years and over                                     | 0     |       |       |
| Age continuous  |       |       |       |
| Units: years  |       |       |       |
| arithmetic mean                                       |       |       |       |
| standard deviation                                    | -     |       |       |
| Gender categorical                                    |       |       |       |
| Units: Subjects                                       |       |       |       |
| Female  | 67    |       |       |
| Male  | 30    |       |       |
| Race  |       |       |       |
| Units: Subjects                                       |       |       |       |
| White   | 82    |       |       |
| Asian   | 13    |       |       |
| Other   | 2     |       |       |
| Skin phototype  |       |       |       |
| Units: Subjects                                       |       |       |       |
| Phototype I   | 7     |       |       |
| Phototype II  | 31    |       |       |
| Phototype III   | 39    |       |       |
| Phototype IV  | 15    |       |       |
| Phototype V   | 5     |       |       |
| Investigator Global Assessment                        |       |       |       |
| Investigator Global Assessment of acne                |       |       |       |
| Units: Subjects                                       |       |       |       |
| 1: Almost clear                                       | 12    |       |       |
| 2: Mild   | 59    |       |       |
| 3: Moderate   | 26    |       |       |

|                    |   |  |  |
|--------------------|---|--|--|
| Acne history       |   |  |  |
| Units: years       |   |  |  |
| arithmetic mean    |   |  |  |
| standard deviation | - |  |  |

## End points

### End points reporting groups

|                                |  |
|--------------------------------|--|
| Reporting group title          | Standard of care + supplementary education |
| Reporting group description: - |  |
| Reporting group title          | Standard of care                           |
| Reporting group description: - |  |
| Reporting group title          | Standard of care + additional visits       |
| Reporting group description: - |  |

### Primary: Mean rate of adherence, as assessed by Medical Event Monitoring System (MEMS)

|  |   |
|--|---|
| End point title  | Mean rate of adherence, as assessed by Medical Event Monitoring System (MEMS) |
| End point description:<br>To prevent bias, treatment adherence was assessed without subject's knowledge using a Medication Event Monitoring System( MEMS). The treatment was placed in a container fitted with a MEMS cap which recorded the time/date every time it was opened and/or closed. A day with at least one opening was considered a day the subject was adherent. Mean rate of adherence in % corresponds to the number of days the subject was adherent divided by the total number of days of the study (84 days) times 100. Analysis was performed on the "worst-case" population: missing data were considered as non-adherence. |   |
| End point type   | Primary   |
| End point timeframe:<br>Week 12  |   |

| End point values                     | Standard of care + supplementary education | Standard of care  | Standard of care + additional visits |  |
|--------------------------------------|--|-------------------|--------------------------------------|--|
| Subject group type                   | Reporting group                            | Reporting group   | Reporting group                      |  |
| Number of subjects analysed          | 20 <sup>[1]</sup>                          | 28 <sup>[2]</sup> | 23 <sup>[3]</sup>                    |  |
| Units: Percentage of adherence       |  |                   |                                      |  |
| arithmetic mean (standard deviation) | 63.1 (± 30.2)                              | 56.5 (± 24.8)     | 48.2 (± 33.9)                        |  |

Notes:

[1] - Worst-case population

[2] - Worst-case population

[3] - Worst-case population

### Statistical analyses

|                            |   |
|----------------------------|---|
| Statistical analysis title | Comparison SoC + education vs SoC                             |
| Comparison groups          | Standard of care + supplementary education v Standard of care |



|   |                         |
|---|-------------------------|
| Number of subjects included in analysis | 48                      |
| Analysis specification                  | Pre-specified           |
| Analysis type                           | equivalence             |
| P-value                                 | = 0.3165                |
| Method                                  | Cochran-Mantel-Haenszel |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Comparison SoC + education vs SoC + visits  |
| Comparison groups                       | Standard of care + supplementary education v Standard of care + additional visits |
| Number of subjects included in analysis | 43  |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | equivalence   |
| P-value                                 | = 0.0206  |
| Method                                  | Cochran-Mantel-Haenszel   |

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Week 12

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 13.0 |
|--------------------|------|

### Reporting groups

|                       |  |
|-----------------------|--|
| Reporting group title | Standard of care + supplementary education |
|-----------------------|--|

Reporting group description: -

|                       |                  |
|-----------------------|------------------|
| Reporting group title | Standard of care |
|-----------------------|------------------|

Reporting group description: -

|                       |                                      |
|-----------------------|--------------------------------------|
| Reporting group title | Standard of care + additional visits |
|-----------------------|--------------------------------------|

Reporting group description: -

| <b>Serious adverse events</b>                     | Standard of care + supplementary education | Standard of care | Standard of care + additional visits |
|---|--|------------------|--------------------------------------|
| Total subjects affected by serious adverse events |  |                  |                                      |
| subjects affected / exposed                       | 0 / 33 (0.00%)                             | 0 / 33 (0.00%)   | 0 / 31 (0.00%)                       |
| number of deaths (all causes)                     | 0  | 0                | 0                                    |
| number of deaths resulting from adverse events    | 0  | 0                | 0                                    |

Frequency threshold for reporting non-serious adverse events: 2 %

| <b>Non-serious adverse events</b>                     | Standard of care + supplementary education | Standard of care | Standard of care + additional visits |
|---|--|------------------|--------------------------------------|
| Total subjects affected by non-serious adverse events |  |                  |                                      |
| subjects affected / exposed                           | 7 / 33 (21.21%)                            | 6 / 33 (18.18%)  | 15 / 31 (48.39%)                     |
| Injury, poisoning and procedural complications        |  |                  |                                      |
| Ligament sprain                                       |  |                  |                                      |
| subjects affected / exposed                           | 0 / 33 (0.00%)                             | 0 / 33 (0.00%)   | 2 / 31 (6.45%)                       |
| occurrences (all)                                     | 0  | 0                | 2                                    |
| Skin and subcutaneous tissue disorders                |  |                  |                                      |
| Acne  |  |                  |                                      |
| subjects affected / exposed                           | 1 / 33 (3.03%)                             | 1 / 33 (3.03%)   | 3 / 31 (9.68%)                       |
| occurrences (all)                                     | 1  | 1                | 3                                    |
| Dry skin  |  |                  |                                      |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed             | 0 / 33 (0.00%) | 2 / 33 (6.06%) | 2 / 31 (6.45%) |
| occurrences (all)                       | 0              | 2              | 2              |
| Erythema                                |                |                |                |
| subjects affected / exposed             | 1 / 33 (3.03%) | 0 / 33 (0.00%) | 2 / 31 (6.45%) |
| occurrences (all)                       | 1              | 0              | 2              |
| Pain of skin                            |                |                |                |
| subjects affected / exposed             | 0 / 33 (0.00%) | 0 / 33 (0.00%) | 2 / 31 (6.45%) |
| occurrences (all)                       | 0              | 0              | 2              |
| Rash                                    |                |                |                |
| subjects affected / exposed             | 1 / 33 (3.03%) | 1 / 33 (3.03%) | 1 / 31 (3.23%) |
| occurrences (all)                       | 1              | 1              | 1              |
| Skin burning sensation                  |                |                |                |
| subjects affected / exposed             | 0 / 33 (0.00%) | 0 / 33 (0.00%) | 2 / 31 (6.45%) |
| occurrences (all)                       | 0              | 0              | 3              |
| Skin irritation                         |                |                |                |
| subjects affected / exposed             | 2 / 33 (6.06%) | 1 / 33 (3.03%) | 0 / 31 (0.00%) |
| occurrences (all)                       | 2              | 1              | 0              |
| Infections and infestations             |                |                |                |
| Viral upper respiratory tract infection |                |                |                |
| subjects affected / exposed             | 2 / 33 (6.06%) | 1 / 33 (3.03%) | 1 / 31 (3.23%) |
| occurrences (all)                       | 2              | 1              | 1              |

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported